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Introduction {#sec1}
============

The development of multicellular systems requires that multipotent progenitors differentiate into specialized lineage-restricted daughter cells. The adoption of a particular cell fate by multipotent cells is orchestrated by networks of transcription factors, which act to coordinate changes in gene expression commensurate with the ultimate function of the cell fate in question. Commitment of multipotent cells to a particular lineage often requires the silencing of gene products that are incompatible with the function of end-product cells. For instance, during hematopoiesis, erythroid and myeloid lineage genes are silenced during the generation of lymphocyte-biased progenitors ([@bib30]) and B cell and myeloid-affiliated genes are actively repressed in early T lineage cells ([@bib49]; [@bib51]). Understanding the regulation of cell fate decisions in hematopoiesis should provide insights into the development of a wide array of multicellular systems and lead to strategies to enhance or limit the generation of particular cell types.

Early B cell development is regulated by several transcription factors. These include Ikaros and PU.1, which promote the generation of lymphoid-biased precursors, and early B cell factor-1 (EBF1), Pax5, and the E2a isoforms E12 and E47 (encoded by the *Tcf3 locus*), which coordinate the differentiation of lymphoid progenitors into lineage-restricted pro-B cells (reviewed in [@bib26]). Given that each of these factors is essential for generating B cell lineage precursors, much work has been devoted to identifying regulated and coregulated target genes. *Ebf1, Pax5,* and *Tcf3* gene products synergize to activate the expression of the pre-BCR components λ5 and VpreB and the B cell signaling protein Ig-α (encoded by *Igll1, Vpreb1*, and *Cd79a,* respectively) (reviewed in [@bib6]; [@bib14]). Notably, *Pax5*, *Ebf1*, and *Tcf3* gene products are each proposed to suppress differentiation of alternative fates ([@bib19]; [@bib31]; [@bib33]). In this regard, Pax5 is regarded as the dominant determinant of B cell commitment, because deletion of *Pax5* in pro-B cells or mature peripheral B cells allows these cells to adopt alternative fates ([@bib8]; [@bib29]). A key but unresolved question is whether E12 and E47 and/or EBF1 promote B cell lineage restriction by collaborating with Pax5 or whether these factors are components of distinct transcriptional circuits important for acquiring and perhaps maintaining B cell identity.

In the thymus, the T cell program is initiated when the earliest defined T cell precursors (ETPs) encounter ligands for the Notch receptor family ([@bib35]). Stimulation of Notch1 on ETPs by the Notch ligand delta-like-4 (DL4) promotes the expression of T-cell-affiliated transcription factors including TCF1 (encoded by *Tcf7*), which in turn promotes the expression of many genes required for T cell function ([@bib46]). However, early T cell development is also controlled by the zinc finger transcription factor GATA3. Indeed, GATA3 is essential for very early T cell development in the thymus beginning at the ETP stage ([@bib16]; [@bib41]), and optimal *Notch1* expression may require GATA3 ([@bib47]). Suppression of the T cell fate in B cells is thought to occur through the *Pax5*-driven repression of *Notch1* ([@bib40]). However, we showed previously that EBF1 prevents myeloid and T cell differentiation when introduced into *Pax5*^*−/−*^ progenitors ([@bib33]). The latter observation suggests that Pax5-independent transcriptional pathways may also regulate B cell lineage restriction, while also raising questions about the mechanism(s) employed by EBF1 to constrain T cell differentiation.

Here, we utilize a series of gain- and loss-of-function approaches to uncover the transcriptional mechanism underpinning EBF1-mediated suppression of T cell development. Our findings indicate that EBF1 limits early T cell differentiation by directly repressing *Gata3* transcription and suggest that EBF1 silences *Gata3* expression by promoting repressive histone modifications across *Gata3* regulatory regions. These data identify a transcriptional circuit critical for preventing T cell differentiation and adopting the B cell fate.

Results {#sec2}
=======

EBF1 Suppresses T Cell Differentiation in B-Cell-Lineage-Biased Lymphoid Progenitors {#sec2.1}
------------------------------------------------------------------------------------

Lymphoid-biased progenitors in the bone marrow (BM), also referred to as common lymphoid progenitors (CLPs) ([@bib22]), can be subdivided into several subpopulations. More mature B-cell-lineage-biased progenitors within this heterogeneous population are also termed pre-pro-B cells and are characterized by progressive loss of T cell potential coincident with expression of the surface proteins B220 and/or Ly6D ([@bib20]; [@bib34]). Other researchers have employed a λ5 transgene to mark B-cell-lineage-biased precursors in these pools ([@bib28]). Given the rarity of these cells (less than 0.2% of all BM cells) and the diverse approaches used to resolve these populations, we developed a flow cytometric strategy based on differential surface expression of B220 and Ly6D on lymphoid-biased progenitors defined previously as Lineage(Lin)^−^CD19^−^IL-7Rα^+^Flt3^+^Sca1^lo^c-Kit^lo^ ([@bib1]). With this approach we resolved three populations of IL-7Rα^+^Flt3^+^Sca1^lo^c-Kit^lo^ cells defined as B220^−^Ly6D^−^, B220^+^Ly6D^−^, and B220^+^Ly6D^+^ in both wild-type and *Ebf1*^*−/−*^ mice ([Figure 1](#fig1){ref-type="fig"}A and [Figure S1](#app3){ref-type="sec"}A available online). Consistent with past work ([@bib34]), coexpression of B220 and Ly6D correlated with increased *Ebf1*, *Pax5*, and *Rag1* expression ([Figure S1](#app3){ref-type="sec"}B), and when sorted from wild-type mice, the B220^+^Ly6D^+^ subset possessed fewer cells with T cell lineage potential ([Figure 1](#fig1){ref-type="fig"}B; [@bib20]; [@bib34]). Notably, however, although *Ebf1*^*−/−*^ B220^+^Ly6D^+^ precursors were not substantially altered in number or phenotype compared to their wild-type counterparts ([Figure 1](#fig1){ref-type="fig"}A), they exhibited increased T cell lineage potential in both bulk and single-cell cultures ([Figures 1](#fig1){ref-type="fig"}B and 1C). These data extend past analyses ([@bib50]) by showing that EBF1 constrains T cell potential as B-cell-lineage-biased B220^+^Ly6D^+^ progenitors give rise to B-cell-lineage-restricted precursors.

EBF1 Overrides Overt T Cell Induction by Notch1 and TCF1 {#sec2.2}
--------------------------------------------------------

To test directly whether EBF1 prevents very early T cell differentiation independently of Pax5, we sorted BM progenitors from *Pax5*^*−/−*^ fetal liver, transduced these cells with control or EBF1-expressing retrovirus, and then resorted transduced (GFP^+^) cells onto OP9-DL4 stromal cells. As shown ([Figure 2](#fig2){ref-type="fig"}A), despite stimulation with DL4, upon enforced EBF1 expression, *Pax5*^*−/−*^ progenitors generated substantially fewer T lineage cells compared to controls. Enforcing EBF1 expression also prevented T cell development from *Ebf1*^*−/−*^ and *Pax5*^*−/−*^ LSKs transduced with an active allele for *Notch1* (ICN1) ([Figures 2](#fig2){ref-type="fig"}B and [S2](#app3){ref-type="sec"}). Likewise, EBF1 prevented T cell differentiation from progenitors transduced with the Notch1 target *Tcf7* (encoding TCF1) ([Figure 2](#fig2){ref-type="fig"}C; [@bib46]). These data indicate that EBF1 can override T-cell-lineage-promoting signals mediated by the Notch1-TCF1 pathway and further support the notion that EBF1 limits cell-intrinsic T cell potential in lymphoid precursors independently of Pax5.

EBF1 Represses the Generation of *Gata3* Transcripts {#sec2.3}
----------------------------------------------------

To test whether EBF1 represses the expression of essential T cell lineage genes, we transduced an *Ebf1*^*−/−*^ progenitor cell line corresponding to pre-pro-B cells with EBF1 ([@bib33]) and analyzed changes in gene expression on Affymetrix microarrays. In these experiments, transcripts for *Gata3* declined reproducibly, whereas *Notch1* and *Tcf7* transcript levels as well as the T cell lineage regulator Bcl11b were not altered or increased slightly ([Figure S3](#app3){ref-type="sec"}A). We repeated these analyses but with quantitative RT-PCR and locus-specific probes in *Ebf1*^*−/−*^ progenitors transduced with virus encoding EBF1 and/or Pax5. Transduction with EBF1 or Pax5 led to the expected upregulation of transcripts for *Igll1* and *Vpreb1* encoding components of the pre-BCR, and cotransduction with EBF1 and Pax5 resulted in a synergistic increase in abundance of these transcripts ([Figure 3](#fig3){ref-type="fig"}A). Consistent with past work ([@bib40]), transduction with Pax5 reduced Notch1 transcript abundance to 50% of controls. Of note, EBF1 transduction did not perturb *Tcf7* transcription substantially and appeared to drive a modest increase in *Notch1* expression that was overridden by coexpression of Pax5. In sharp contrast, EBF1 transduction consistently induced an 80% decline in *Gata3* transcript abundance ([Figure 3](#fig3){ref-type="fig"}A, top left). Pax5 transduction, by comparison, led to only a modest reduction in *Gata3* transcripts, and cells cotransduced with EBF1 and Pax5 mirrored transduction with EBF1 alone. Introduction of EBF1 into a *Pax5*^*−/−*^ pro-B cell line ([@bib36]) also repeatedly resulted in a 50% decline in *Gata3* transcripts ([Figure 3](#fig3){ref-type="fig"}B), and EBF1 expression continued to promote the downregulation of *Gata3* transcripts in cells cotransduced with ICN1 or TCF1 ([Figure 3](#fig3){ref-type="fig"}C).

Next, we analyzed *Gata3*, *Notch1*, and *Tcf7* transcript abundance in wild-type and *Ebf1*^*−/−*^ Lin^−^CD19^−^IL-7Rα^+^Flt3^+^Sca1^lo^c-Kit^lo^B220^+^ BM lymphoid progenitors subdivided based on differential Ly6D surface expression (see [Figure 1](#fig1){ref-type="fig"}). Remarkably, wild-type B220^+^Ly6D^+^ progenitors exhibited a 7- to 10-fold decrease in *Gata3* transcripts compared to cells within the less mature B220^+^Ly6D^−^ fraction ([Figure 3](#fig3){ref-type="fig"}D), indicating that decreased *Gata3* expression correlates with loss of T cell lineage potential. Furthermore, *Ebf1*^*−/−*^ B220^+^Ly6D^+^ precursors exhibited a robust increase in *Gata3* transcripts compared to their wild-type counterparts to levels found in wild-type B220^+^Ly6D^−^ progenitors. In contrast, we observed only a modest increase in *Notch1, Tcf7* transcripts in B220^+^Ly6D^+^ precursors lacking *Ebf1*. As expected, expression of the canonical EBF1 target *Igll1* was severely decreased in *Ebf1*^*−/−*^ B220^+^Ly6D^+^ progenitors ([Figure 3](#fig3){ref-type="fig"}D, right-most panel). These data, together with the data in [Figure 1](#fig1){ref-type="fig"}, show that deletion of *Ebf1* results in increased *Gata3* transcripts and a corresponding increase in T cell lineage potential in B-cell-lineage-biased lymphoid progenitors, implicating EBF1-mediated repression of *Gata3* as an important event in early B cell development.

Mechanisms of EBF1-Mediated *Gata3* Repression {#sec2.4}
----------------------------------------------

Given that early B cell development involves collaborative interactions between EBF1 and the E12 and E47 transcription factors encoded by the *Tcf3* gene ([@bib24]; [@bib38]), we tested whether EBF1-driven downregulation of *Gata3* mRNA expression required *Tcf3*-encoded proteins. For these experiments we employed 4-hydroxytamoxifen (4-OHT)-responsive fusion proteins consisting of either the E47 or EBF1 coding regions fused to a mutated ligand-binding domain of estrogen receptor-α (referred to as E47:ER or EBF1:ER, respectively) ([@bib21]; [@bib48]). These constructs were introduced into *Tcf3*^*−/−*^ or *Ebf1*^*−/−*^ progenitors and routinely resulted in nearly 100% GFP^+^ cells (not shown). Notably, whereas induction of E47:ER in *Tcf3*^*−/−*^ progenitors led to only a 2-fold decrease in *Gata3* transcripts 12 hr later ([Figure S3](#app3){ref-type="sec"}B), induction of EBF1:ER expression resulted in a 5-fold decrease in *Gata3* mRNA within 12 hr, similar to experiments with *Ebf1*^*−/−*^ progenitors ([Figure S3](#app3){ref-type="sec"}C). Moreover, after only 4 hr, induction of EBF1:ER in *Tcf3*^*−/−*^ progenitors led to a significant loss in *Gata3* transcript abundance ([Figure S3](#app3){ref-type="sec"}C, left). As expected, in this system induced EBF1:ER caused robust increases in *Igll1* transcripts ([Figure S3](#app3){ref-type="sec"}C, right). These data indicate that silencing of GATA3 expression by EBF1 does not strictly require E2a proteins.

We also adopted several approaches that together indicate that EBF1 represses *Gata3* expression directly. First, we tested whether inhibition of protein synthesis with cycloheximide (CHX) prevents EBF1-driven decreases in *Gata3* transcripts. For these experiments we employed *Tcf3*^−/−^ and *Ebf1*^−/−^ progenitors containing 4-OHT-regulated EBF1:ER. *Gata3* downregulation still occurred when transduced *Tcf3*^*−/−*^ or *Ebf1*^*−/−*^ progenitors were preincubated with CHX for 8 hr before adding 4-OHT ([Figure S3](#app3){ref-type="sec"}D). Likewise, increases in *Igll1* transcripts were also intact in CHX-pretreated cells ([Figure S3](#app3){ref-type="sec"}E). To test further the possibility that EBF1 mediates silencing of *Gata3* indirectly by activating an unknown transcriptional repressor, we determined whether conversion of EBF1 into an obligate repressor prevented EBF1-mediated downregulation of *Gata3*. To this end we fused the DNA binding domain of EBF1 to the *Drosophila* Engrailed repression domain ([@bib10]; [@bib45]). The resulting EBF1-Engrailed protein readily repressed transcription of *Igll1* when introduced into *Ebf1*^*−/−*^ pre-pro-B cells ([Figure 4](#fig4){ref-type="fig"}A, left). However, EBF1-Engrailed continued to decrease transcript abundance for *Gata3* similar to wild-type EBF1 ([Figure 4](#fig4){ref-type="fig"}A, right). Together these data suggest that EBF1 regulates *Gata3* mRNA levels directly.

We utilized the ECR-browser database (<http://ecrbrowser.dcode.org>) to determine whether the *Gata3* locus contains conserved EBF1 binding sequences. We noted two such sites within the *Gata3* locus, one upstream of the *Gata3* promoter 1b ("site a," ∼2,350 bases from the transcriptional start site 1b) and a second site within the second intron ("site b," ∼3,290 bases downstream of transcriptional start site 1b) ([Figure S4](#app3){ref-type="sec"}A). Notably, past data indicate that the intronic regions of *Gata3* play fundamental roles in regulating its expression ([@bib18]). We performed ChIP experiments with EBF1 antibodies and PCR primers flanking either putative EBF1 binding site ([Table S1](#app3){ref-type="sec"}). Target populations included CD19^+^ BM B lineage cells, the *Ebf1*^*−/−*^ progenitor cell line, and wild-type CD3ε^+^ splenic T cells. We observed a 4- to 6-fold enrichment in EBF1 binding at each site in CD19^+^ BM cells but not *Ebf1*^*−/−*^ progenitors or peripheral T cells ([Figure 4](#fig4){ref-type="fig"}B). We also failed to detect EBF1 binding from a gene desert region on mouse chromosome 6 in *Ebf1*^*−/−*^ progenitors and CD19^+^ BM cells (not shown). In addition, a 24 base pair biotin-labeled DNA probe encompassing "site a" led to formation of a protein-DNA complex in electrophoretic mobility shift assays using nuclear extracts from 293T cells transfected with a His~6~-tagged version of EBF1, which was super-shifted by an anti-histidine antibody. This complex failed to form when we used a probe in which the putative EBF1 site was mutated and was reduced substantially upon inclusion of an unlabeled wild-type *Cd79a* probe containing a canonical EBF1 binding site ([Figure S4](#app3){ref-type="sec"}B). These data further support a model whereby EBF1 mediates the direct repression of *Gata3* transcription.

To probe the mechanism underlying repression of *Gata3*, we tested whether EBF1 promotes epigenetic changes proximal to EBF1 binding sites associated with transcriptional repression. First, we explored the possibility that EBF1 promotes DNA methylation of CpG residues. Though the *Gata3* promoter and second intron both contain prominent CpG islands adjacent to the EBF1 binding sites ([@bib3]), by sodium bisulfite sequencing we did not detect changes in the methylation status of these regions in multipotent lymphoid progenitors versus pro-B cells (not shown). Because gene silencing can be mediated by histone modifications independently of DNA methylation ([@bib23]), we also evaluated repression-associated histone-methylation signatures upon ectopic EBF1 expression. We performed ChIP experiments with a H3K27me3-specific antibody, because stable transcriptional silencing is tightly associated with trimethylation of H3K27 ([Table S1](#app3){ref-type="sec"}; [@bib4]). CD19^+^ BM cells were highly enriched for H3K27me3 marks in the *Gata3* locus, although this was not the case for *Ebf1*^*−/−*^ progenitors ([Figure 4](#fig4){ref-type="fig"}C). Again, the gene desert region on chromosome 6 was included as an additional negative control (data not shown). Furthermore, transduction of *Ebf1*^*−/−*^ progenitors with EBF1 readily induced the acquisition of H3K27me3 marks on chromatin surrounding both EBF1 binding sites ([Figure 4](#fig4){ref-type="fig"}D). These data suggest that EBF1 orchestrates epigenetic changes at the *Gata3* locus by directly or indirectly recruiting polycomb (PcG) group complexes that impart repressive H3K27me3 modifications to this region.

Functional Relevance of *Gata3* Repression {#sec2.5}
------------------------------------------

We sought to test whether ectopic expression of progenitors with GATA3 would bypass EBF1-mediated suppression of T cell differentiation. To this end we cotransduced *Ebf1*^*−/−*^ progenitors with EBF1 and GATA3 before sorting these cells on OP9-DL4 cultures. However, consistent with past work indicating that transduction of lymphoid progenitors with GATA3 readily induces apoptosis ([@bib41]), there was a progressive decline in viable GATA3-positive cells after transduction ([Figure S5](#app3){ref-type="sec"}A). We also considered generating transgenic mice as an alternative approach to achieving increased GATA3 expression. However, given that *Gata3* expression is regulated by distal enhancer elements ([@bib17]), we concluded that this approach was unlikely to succeed. Consequently, we tested whether blocking EBF1 binding to *Gata3* regulatory sites prevented EBF1-driven suppression of early T cell differentiation. Indeed, we reasoned that a failure of EBF1 to bind to and repress the *Gata3* locus should result in increased *Gata3* expression, thereby providing an alternative approach for increasing GATA3 expression in lymphoid progenitors. To this end, we designed a retroviral construct (pMX-6ZFP) to express a synthetic hexa-modular Zinc-finger protein (6ZFP) specific for an 18 base region including the last seven nucleotides of the 8 base core EBF1 binding site between exons 1a and 1b ("site a") of the *Gata3* locus ([Figure S5](#app3){ref-type="sec"}B). We were unable to engineer a Zn-finger protein to block binding of EBF1 to "site b" because of inadequate target site overlap requirements (see [Experimental Procedures](#sec4){ref-type="sec"}). The individual modular domains of 6ZFP were linked via a polydactyl zinc finger assembly strategy for recognizing extended sequences ([@bib13]). The nucleotide and predicted amino acid sequences for 6ZFP are shown in [Table S2](#app3){ref-type="sec"}. A VP64 transcriptional activation domain was included to counter any potential stalling effect of 6ZFP on endogenous transcription ([@bib5]), and a hemagglutinin (HA) tag was added for assessing 6ZFP binding to particular DNA segments. Control constructs included retroviruses lacking a polypeptide encoding insert (pMX) and a second construct encoding an unrelated nonfunctional peptide (pMX-SS). Expression of 6ZFP was tracked via cotranslation of GFP from an IRES element. Significantly, after transduction of wild-type LSKs with pMX-6ZFP, the 6ZFP protein readily occupied "site a" as predicted, but we were unable to detect occupancy of 6ZFP at "site b" or at canonical EBF1 binding sites within the *Cd79a* or *Igll1* loci ([Figure 5](#fig5){ref-type="fig"}A). In contrast, pMX-transduced cells failed to exhibit 6ZFP enrichment at any of these sites.

*Pax5*^*−/−*^ progenitors were transduced with YFP-marked EBF1 virus and/or one of the aforementioned pMX constructs and then cultured on OP9-DL4 stromal cells for 7 days. As shown ([Figure 5](#fig5){ref-type="fig"}B), whereas EBF1 expression alone led to the expected reduction in Thy1.2^+^CD25^+^ T lineage cells, cotransduction with EBF1 and pMX-6ZFP but not with EBF1 and either control pMX constructs restored numbers of T lineage cells to 50% of that observed in cells transduced with pMX-6ZFP alone (pMX-SS data not shown). As expected, 6ZFP expression led to decreased enrichment for EBF1 between exons 1a and 1b without affecting EBF1 binding between exons 2 and 3 ([Figure 5](#fig5){ref-type="fig"}C). Moreover, cotransduction with pMX-6ZFP and EBF1 restored *Gata3* mRNA levels to 50% of EBF1-transduced cells ([Figure 5](#fig5){ref-type="fig"}D), and pMX-6ZFP expression alone increased *Gata3* mRNA levels 2-fold compared to cells transduced with pMX (not shown).

Notably, the increased levels of *Gata3* induced with 6ZFP expression correlated with decreased differentiation of B220^+^CD19^+^ B lineage cells from wild-type fetal liver cells cotransduced with EBF1 ([Figure 6](#fig6){ref-type="fig"}A), suggesting that elevated *Gata3* mRNA levels, in part due to reduced EBF1 occupancy within "site a," perturbed early B cell development. To test this hypothesis directly, we introduced pMX or pMX-6ZFP into BM LSKs and CLPs sorted from either *Vav*^Cre^ transgenics or *Vav*^Cre^*Gata3*^fl/fl^ mice and then sorted GFP^+^ cells from these cultures onto OP9 stromal cells. Strikingly, although 6ZFP prevented B cell differentiation when introduced into GATA3-competent lymphoid progenitors, early B cell differentiation was restored upon deletion of *Gata3* ([Figure 6](#fig6){ref-type="fig"}B). Altogether these findings indicate that direct EBF1-mediated repression of *Gata3* transcription is critical for extinguishing T cell lineage choice and allowing lymphoid progenitors to adopt the B cell fate.

Repression of GATA3 in T-Lineage-Committed Cells {#sec2.6}
------------------------------------------------

Finally, to probe whether EBF1 can repress *Gata3* in T-lineage-committed cells, we assessed whether survival of GATA3-dependent *Tcf3*^*−/−*^ 1.F9 thymoma cells ([@bib48]) is perturbed upon introducing EBF1. Transduction of 1.F9 cells with EBF1 led to a 5-fold reduction of *Gata3* transcript abundance in these cells ([Figure S6](#app3){ref-type="sec"}A). Whereas control virus did not affect viability over 8 days, introducing EBF1 decreased cell viability to less than 20% within 4 days ([Figure S6](#app3){ref-type="sec"}B). Consistent with past data ([@bib48]), loss of viability correlated with accumulation of the active form of proapoptotic caspase 3 ([Figures S6](#app3){ref-type="sec"}C). Moreover, both cell death and active caspase 3 generation were reversed upon enforced coexpression of EBF1 and GATA3 in 1.F9 cells ([Figures S6](#app3){ref-type="sec"}D and S6E). These data further support a model whereby EBF1 constrains T cell differentiation by silencing *Gata3* expression and further suggest that EBF1 may limit T cell development by perturbing GATA3-dependent survival mechanisms.

Discussion {#sec3}
==========

Our results provide insights into the transcriptional circuitry responsible for generating early B-cell-lineage-restricted precursors. Whereas deletion of *Ebf1* in B-cell-lineage-biased lymphoid progenitors catalyzed an increase in *Gata3* transcript abundance concurrent with a rejuvenation in their T cell potential, enforcing EBF1 repressed T cell differentiation and *Gata3* mRNA levels, even in *Pax5*-deficient progenitors and despite ectopic Notch1 and TCF1 activity. Perhaps most notably, perturbation of EBF1 binding at a *Gata3* regulatory region interfered with EBF1-driven suppression of early T cell differentiation, concomitantly preventing B cell differentiation due to increased *Gata3* expression.

EBF1 is an indispensible component of the transcriptional regulatory framework required for generating pro-B cells. Within this network of transcription factors, E2a proteins activate the expression of *Ebf1* and *Foxo1*, and subsequently EBF1 works in concert with E12 and E47 and Foxo1 to promote *Pax5* expression ([@bib24]). Although these previous studies demonstrate synergism between these transcription factors to activate certain key B-cell-specific molecules, they also raise questions about how specific components of this network might collaborate to constrain alternative fates. Because Pax5 is essential for establishing and maintaining B cell identity ([@bib8]; [@bib29]), one view would be that B cell lineage restriction is mediated chiefly and perhaps exclusively by Pax5. However, our results highlight the ability of EBF1 to suppress T cell differentiation of *Pax5*-deficient progenitors without an immediate decline in *Notch1* transcripts. Furthermore, unlike many genes that are upregulated by EBF1, our data suggest that EBF1 represses *Gata3* transcription without input from E2a proteins. Therefore, we propose that B cell lineage restriction is controlled by two or more separate transcriptional pathways, with Pax5 and EBF1 repressing *Notch1* and *Gata3* expression, respectively. Moreover, in light of past data indicating that E2a proteins are unique among B cell regulatory transcription factors in their ability to repress erythroid differentiation ([@bib19]), B cell lineage commitment may be facilitated by a variety of transcriptional and temporally distinct mechanisms. In this model, E2a proteins would silence erythroid and perhaps myeloid potentials as lymphoid-biased progenitors develop, EBF1 would silence T cell potential as well as residual myeloid potentials during adoption of the B cell fate, and Pax5 would silence alternative fates after the generation of pro-B cells. This viewpoint is consistent with recent data suggesting that suppression of alternative fates during T cell commitment also requires the activity of multiple transcriptional pathways ([@bib51]). Further work, including an evaluation of the potential role played by EBF1 in maintaining mature B cell identity and the role of other transcriptional regulators and cofactors in this process, may shed additional light on whether maintenance of the B cell fate also requires input from multiple transcription factors.

Although the role of GATA3 in peripheral T cell differentiation has been studied intensively ([@bib2]; [@bib10]), recent studies together with our findings emphasize the essential role played by GATA3 in very early stages of T cell development. In the thymus, Notch1 signaling in early T lineage cells induces the expression of additional regulators including *Hes1* and *Tcf7*. In turn, TCF1 promotes the expression of numerous genes required for T cell development and function ([@bib46]), but *Tcf7*-deficient mice continue to generate T cells, albeit with decreased numbers ([@bib37]). By contrast, *Gata3*-deficient progenitors fail to generate T lineage cells beyond the ETP stage of early thymocyte development ([@bib16]; [@bib41]). Indeed, recent data suggest that GATA3 activity may be essential for optimal *Notch1* expression in ETPs, as shown by the fact that GATA3 binds to the *Notch1* promoter in early thymocytes and that deletion of *Gata3* in thymocytes reduces *Notch1* transcripts ([@bib47]). Moreover, GATA3 occupies distinct sets of regulatory regions at different stages of thymocyte development ([@bib51]), suggesting that GATA3 regulates many diverse aspects of T cell development downstream of Notch1 activation. The latter viewpoint is supported by our data showing that EBF1 prevents T cell differentiation despite ectopic Notch1 activity or enforced TCF1 expression. Altogether, these collective observations indicate that *Gata3* constitutes a prime target for regulatory pathways that silence the T cell fate in early B lineage cells.

The mechanisms governing transcriptional activation of EBF1 target genes have been studied intensively ([@bib15]; [@bib25]; [@bib39]). By contrast, how EBF1 represses transcription of certain loci is only beginning to be addressed ([@bib12]). Recent analyses of EBF1 occupancy of genes across the B cell genome suggest that the vast majority of EBF1 targets are located in transcriptionally active regions ([@bib44]). Therefore, the default mode for EBF1 may be as a transcriptional activator. However, other EBF1 target loci were found in transcriptionally inactive regions, and EBF1 has also been shown to downregulate the expression of the E-protein regulators Id2 and Id3 ([@bib43]). Therefore, EBF1 may repress additional important loci during establishment and maintenance of the B cell fate.

The use of synthetic Zn fingers such as our 6ZFP construct to evaluate the role of defined *cis* elements may prove useful in studying other region-specific protein-DNA interactions in a wide variety of biological and experimental contexts. However, interpretation of data derived from this approach could be confounded by off-target DNA binding events. Here, 6ZFP did not appear to bind to alternative EBF1 binding sites within the *Gata3*, *CD79a*, or *Igll1* locus and led to the predicted outcomes in *Gata3* mRNA levels and T and B cell differentiation. Nonetheless, 6ZFP may bind to additional undefined elements across the genome. We considered performing ChIP-seq experiments to determine the identity of these alternative elements, but we suspect strongly that the functional relevance of these sites would be obscure at best. Indeed, recent genome-wide analyses of DNA occupancy by EBF1 suggest that endogenous transcription factors may also bind to a wide range of elements with unknown functional relevance ([@bib44]). Therefore, although synthetic proteins containing six tandem Zn fingers such as 6ZFP may prove to possess minimal off-target effects ([@bib11]), validating the specificity of such proteins with a particular biological outcome may require the use of cells bearing appropriate mutations.

Finally, although the precise molecular details remain unclear, we hypothesize that the switch between activator and repressor functions of EBF1 at different loci reflects differential spatio-temporal interactions of EBF1 with coactivator and corepressor complexes, which in turn would be dictated by diverse proximal and/or distal *cis* elements. Our results show that EBF1 binding within the *Gata3* locus is associated with repressive H3K27me3 marks on nearby chromatin. These results implicate EBF1 in the active recruitment of polycomb group (PcG) repressor complexes. Currently the chief mediator of H3K27me3 modifications in eukaryotes is the protein enhancer of zeste 2 (Ezh2), a member of the polycomb repressor complex 2 (PRC2) ([@bib7]). PRC2 activity in turn attracts PRC1, which prevents transcriptional initiation by RNA polymerase II ([@bib9]). Therefore, it is tempting to suggest that EBF1 binding at the *Gata3* locus directly or indirectly initiates mobilization of PRC2 complexes to this region, thereby blocking interactions with coactivators and stabilizing chromatin modifications associated with long-term transcriptional silencing. Assuming that this sequence of events is indeed contingent on sequence-specific corepressors, competitive blockade of their cognate DNA sites via our Zn-finger protein strategy might neutralize repressive effects of EBF1 at the *Gata3* locus. Furthermore, given that histone modification is a dynamic and reversible process ([@bib42]; [@bib51]), it will be informative to test whether induced deletion of EBF1 in B-lineage-committed cells causes the reversal of trimethylation on H3K27 residues in *Gata3* regulatory regions, possibly leading to *Gata3* expression. The consequences of such aberrant expression would give us further clues into the biological significance of *Gata3* silencing in B cells.

Experimental Procedures {#sec4}
=======================

Mice {#sec4.1}
----

C57BL/6 (B6) and B6.Ly5^SJL^ females (6--8 weeks of age) were from the NCI animal facility (Frederick, MD). *Ebf1*^*+/−*^ mice were kindly provided by B. Kee (University of Chicago) with permission from R. Grosschedl (Max Planck Institute, Freiburg). *Pax5*^*+/−*^ mice were kindly provided by M. Busslinger (Research Institute of Molecular Pathology, Vienna). *Gata3*^fl/fl^ and *Vav*^iCre^ mice were kindly provided by J. Zhu (National Institutes of Health) and D. Kioussi (National Institute for Medical Research, London), respectively. All animal experiments were performed according to protocols approved by the Office of Regulatory Affairs of the University of Pennsylvania in accordance with guidelines set forth by NIH and by the local ethics committee at the University of Oxford and the United Kingdom Home Office.

Cell Culture {#sec4.2}
------------

Primary progenitors and progenitor cell lines were cultured as described previously ([@bib33]; [@bib48]). Details are provided in the [Supplemental Information](#app3){ref-type="sec"}.

Plasmids {#sec4.3}
--------

A detailed description of all retroviral plasmids is available in the [Supplemental Information](#app3){ref-type="sec"}. For expression of synthetic Zn-finger polypeptides, the predicted 6ZFP mini-gene sequence was synthesized by Blue Heron Biotech, cloned into the control pMX-VP64-IRES-GFP retroviral construct (C. Barbas, Scripps Research Institute), and renamed pMX-6ZFP. A plasmid eliciting translation of an unrelated nonfunctional peptide (pMX-SS) was also provided by the Barbas lab. A nuclear localization signal sequence (NLS) and hemagglutinin (HA) tag are also included in the pMX vector backbone.

Flow Cytometry {#sec4.4}
--------------

Stained single-cell suspensions were stained and analyzed as described previously ([@bib33]). Details of antibodies and flow cytometers used are available in the [Supplemental Information](#app3){ref-type="sec"}.

Generation of Fetal Liver Chimeras {#sec4.5}
----------------------------------

B6.Ly5^SJL^ hosts were irradiated (900R) 6 hr before intravenous transfer of day 14.5 fetal liver cells isolated from B6 or *Pax5*^−/−^ or *Ebf1*^*−/−*^ embryos.

T Lymphoid Differentiation Assays {#sec4.6}
---------------------------------

Bulk and clonal assays measuring T cell differentiation were performed with OP9-DL4 stromal cells as described previously ([@bib46]) and in the [Supplemental Information](#app3){ref-type="sec"}.

Retroviral Transduction {#sec4.7}
-----------------------

High-titer virus was generated by a CaPO~4~ transfection protocol ([@bib32]). Cultures were supplemented with fresh medium at 12 hr after infection and harvested for downstream applications at indicated time points after infection.

Gene Expression Analyses {#sec4.8}
------------------------

For quantitative RT-PCR, RNA was purified from indicated cell types with the QIAGEN RNeasy Mini Kit and reverse transcribed to cDNA with GE first-strand cDNA synthesis kit. Real-time PCR was performed with inventoried TaqMan probes for indicated genes and analyzed on an ABI Prism 7300 system (Applied Biosystems). 18S rRNA served as endogenous control for all samples. Relative transcript abundance was determined with the ΔΔ*C*t method. Microarray analyses are described in the [Supplemental Information](#app3){ref-type="sec"}.

Chromatin Immunoprecipitation Assays {#sec4.9}
------------------------------------

CD3ε^+^ thymocytes and CD19^+^ BM cells were column selected (Miltenyi Biotec). In case of control vector and EBF1-transduced *Ebf1*^*−/−*^ cells or cells cotransduced with EBF1 and pMX/pMX-6ZFP/pMX-SS viruses, viable GFP^+^ or YFP^+^GFP^+^ cells were sorted either 24 hr or 7 days after infection as indicated. ChIP was performed on indicated cell types (2 × 10^6^ cells/assay) with the ChIP-IT kit (Active Motif). In brief, cells were fixed for 10 min at room temperature with 1% formaldehyde, treated with glycine stop-fix solution, then lysed with dounce-homogenizer. Pelleted nuclei were digested in presence of protease inhibitor cocktail and chromatin was enzymatically sheared. Sheared chromatin was immunoprecipitated with 4 μg anti-EBF1 (a kind gift from R. Grosschedl) or anti-H3K27me3 (07-449, Millipore) or anti-HA (ab9110, Abcam). After washing, bound chromatin was eluted and treated for reversal of crosslinking. After proteinase K digestion, DNA was immediately used in quantitative real-time PCR (SYBR Green, ABI). PCR primer sets are outlined in [Table S1](#app3){ref-type="sec"}. A negative control primer set (Active Motif, catalog number 71011) for an 82 base pair gene desert region on mouse chromosome 6 was included in each immunoprecipitation. Nonenrichment for EBF1 or anti-H3K27me3 at this site served as a ChIP specificity control.

Zinc Finger Protein Design {#sec4.10}
--------------------------

A 48 base pair (bp) sequence spanning the EBF1 binding "site a" (as confirmed by ChIP assays) in *Gata3* genomic locus was selected. Using the publicly available online resource called Zinc Finger Tools (<http://www.scripps.edu/mb/barbas/zfdesign/zfdesignhome.php>), an 18 bp potential target site including the EBF1 binding site was identified and the amino acid sequence of a hexa-modular zinc finger protein (6ZFP) predicted to bind to this site was designed ([Table S2](#app3){ref-type="sec"}). Because of unmet target site overlap requirements, designing 6ZFP for a target site covering the intronic EBF1 binding "site b" was avoided as recommended ([@bib27]).

Statistical Analysis {#sec4.11}
--------------------

The means of each data set were analyzed by Student's t test, with a two-tailed distribution assuming equal sample variance.

Accession Numbers {#app1}
=================

The microarray data are available in the Gene Expression Omnibus (GEO) database (<http://www.ncbi.nlm.nih.gov/gds>) under the accession number [GSE46004](ncbi-geo:GSE46004){#intref0025}.

Supplemental Information {#app3}
========================

Document S1. Supplemental Experimental Procedures, Figures S1--S6, and Tables S1 and S2
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![*Ebf1*-Deficient B-Cell-Lineage-Biased Precursors Possess Increased T Lymphoid Potential\
(A) BM cells from chimeras reconstituted with B6 or B6.*Ebf1*^*−/−*^ fetal liver 12 weeks previously were stained with antibodies to the host-specific determinant CD45^SJL^ and the antibodies shown in [Figure S1](#app3){ref-type="sec"}. 2 × 10^6^ events were collected on an LSR2 flow cytometer and gated as in [Figure S1](#app3){ref-type="sec"}.\
(B) 200 WT or *Ebf1*^*−/−*^ B220^+^Ly6D^−^ or B220^−^Ly6D^+^ cells derived from the indicated chimeras were sorted onto pre-established OP9-DL4 cells supplemented with IL-7, FL, and SCF. Seven days later, cells were counted and analyzed for cell surface marker expression. The mean number of viable (DAPI^−^) CD45^+^ early T cell lineage (Thy1.2^+^CD25^+^) cells in triplicate cultures is shown. Error bars indicate SEMs, ^\*^p \< 0.005. Data are representative of three separate experiments.\
(C) 96 single WT or *Ebf1*^*−/−*^ B220^+^Ly6D^−^ or B220^+^Ly6D^+^ cells were sorted onto pre-established OP9-DL4 cells in flat-bottom 96-well plates with IL-7, FL, and SCF. Wells containing cell growth were counted and analyzed on day 10. Data are representative of two separate experiments. See also [Figure S1](#app3){ref-type="sec"}.](gr1){#fig1}

![Notch1 and TCF1 Fail to Prevent Inhibition of Early T Cell Lineage Differentiation by EBF1\
(A) LSK (Lin^−^Sca1^+^c-kit^+^) cells were sorted from e14.5 *Pax5*^*−/−*^ fetal livers and transduced with control MigR1 or MigR-EBF1 virus. Viable GFP^+^ cells were sorted 24 hr after transduction onto pre-established OP9-DL4 cells with IL-7, FL, and SCF. Seven days later, cultures were stained and analyzed for absolute numbers of DAPI^−^CD45^+^GFP^+^Thy1.2^+^CD25^+^ cells. Data in right-most graph are means and SEMs from each group.\
(B) e14.5 *Ebf1*^*−/−*^ fetal liver LSKs were isolated and cotransduced with MigY-EBF1 and MigR-ICN1 viruses and plated on OP9 stromal cells. A day later, cells were washed and replated on OP9s in fresh media supplemented with IL-7, FL, and SCF. On day 7, cultures were stained and analyzed for relative contribution of DAPI^−^CD45^+^ single-transduced (GFP^+^YFP^−^ or GFP^−^YFP^+^) or double-transduced (GFP^+^YFP^+^) cells that coexpressed Thy1.2 and CD25.\
(C) e14.5 *Ebf1*^*−/−*^ fetal liver LSKs were isolated and cotransduced with MigY-EBF1 and TCF1-VEX viruses as in (B). Plots were gated on DAPI^−^CD45^+^ single- or double-transduced cells. All graphs show means ± SEMs of triplicate samples. Data are representative of three separate experiments. See also [Figure S2](#app3){ref-type="sec"}.](gr2){#fig2}

![EBF1 Represses *Gata3* Transcript Levels\
(A) *Ebf1*^*−/−*^ lymphoid progenitors were transduced with MigR1, MiY-EBF1, or Mig-Pax5 virus alone or cotransduced with MiY-EBF1 and Mig-Pax5 and plated on OP9 cells supplemented with IL-7, FL, and SCF. 50,000 DAPI^−^YFP^+^GFP^−^, YFP^−^GFP^+^, or YFP^+^GFP^+^ cells were sorted 24 hr later for RNA isolation. Transcript levels of the indicated genes were assayed by qRT-PCR. Expression levels in MigR1-transduced samples were set to 1 and sorted pro-B cells (B220^+^CD43^+^AA4.1^+^CD19^+^) were included as an additional control. Error bars indicate SEMs, ^\*^p \< 0.001.\
(B) 2 × 10^7^*Pax5*^*−/−*^ pro-B cells were transduced with control MigR1 or MigR-EBF1 virus and assayed for relative levels of *Gata3* transcripts 24 hr later by sorting on DAPI^−^GFP^+^ cells as in (A). Starting cell numbers were high due to the refractory nature of these cells to retroviral transduction. Error bars indicate SEMs, ^\*^p \< 0.01.\
(C) *Ebf1*^*−/−*^ pre-pro-B cells were single transduced with Mig-ICN1 or TCF1-VEX or cotransduced with MigY-EBF1 and MigR-ICN1 or MigY-EBF1 and TCF1-VEX viruses. Seven days later, RNA was isolated and assayed for relative expression of *Gata3* transcripts as in (A).\
(D) 50,000 B220^+^Ly6D^−^ or B220^+^Ly6D^+^ BM cells were sorted from chimeras established with WT or *Ebf1*^*−/−*^ fetal liver progenitors as in [Figure 1](#fig1){ref-type="fig"}A. cDNA was prepared and qRT-PCR performed as in (A). Expression levels for the indicated genes in WT B220^+^Ly6D^+^ cells were arbitrarily set to 1, except for *Igll1* detection where B220^+^Ly6D^−^ cells were employed. ND, signal not detected. Data are means ± SEMs of triplicate samples. Error bars indicate SEMs, ^\*^p \< 0.001, ^\*\*^p \< 0.01.\
All data are representative of three separate experiments. See also [Figure S3](#app3){ref-type="sec"}.](gr3){#fig3}

![EBF1 Binds to the *Gata3* Locus and Induces Repressive Histone Modifications\
(A) *Ebf1*^*−/−*^ lymphoid progenitors were transduced with a construct encoding an EBF1-Engrailed fusion protein, wild-type EBF1, or control virus. After 12 hr, GFP^+^ cells were harvested, cDNA prepared, and *Igll1* or *Gata3* mRNA levels determined with Taqman primer-probe sets. The data are normalized to transcript levels for either *Igll1* or *Gata3* in cells transduced with MigR1 control virus.\
(B) ChIP via anti-EBF1 was performed with the indicated cell types including CD19^+^ BM lymphocytes and CD3ε^+^ thymocytes. qRT-PCR was performed to amplify immunoprecipitated DNA with flanking primers to sites a or b; detection signals were normalized to input DNA. Data are expressed as fold enrichment over *Ebf1*^*−/−*^ cells, which served as negative control.\
(C) H3K27me3 modifications within sites 1--5 in CD19^+^ BM lymphocytes relative to *Ebf1*^*−/−*^ cells.\
(D) *Ebf1*^*−/−*^ cells were transduced with control MigR1 or MigR-EBF1 virus and plated on OP9 cells in presence of IL-7, FL, and SCF. 24 hr later, DAPI^−^GFP^+^ cells were sorted, fixed, and processed for ChIP. Relative H3K27me3 enrichment at sites 1--5 in EBF1 versus control-transduced samples is shown. Data are means ± SEMs of triplicate samples. Error bars indicate SEMs, ^\*^p \< 0.01, ^\*\*^p \< 0.001. Data are representative of four separate experiments.\
See also [Figures S3 and S4](#app3){ref-type="sec"} and [Table S1](#app3){ref-type="sec"}.](gr4){#fig4}

![Inhibition of EBF1 Binding to the *Gata3* Locus Rescues T Cell Differentiation\
(A) ChIP experiments with HA antibodies were performed on GFP^+^ progenitors transduced 7 days previously with pMX-6ZFP or pMX (control) by site-specific PCR primers.\
(B) Sorted e14.5 *Pax5*^*−/−*^ fetal liver LSKs were cotransduced with pMX-ZF and MigY-EBF1 viruses and then added to OP9 stromal cells. pMX and MigY-EBF1 cotransduced cells served as control. After 24 hr, cells were washed and replated on OP9-DL4 stromal cells in fresh media supplemented with IL-7, FL, and SCF. On day 7, cultures were stained and analyzed for frequencies of Thy1.2^+^CD25^+^ cells among DAPI^−^CD45^+^ single- or double-transduced cells.\
(C) Sorted e14.5 *Ebf1*^*−/−*^ fetal liver LSKs were cotransduced with pMX and MigY-EBF1 or pMX-ZF and MigY-EBF1 viruses, added to OP9 stromal cells. After 7 days, viable YFP^+^GFP^+^ cells were sorted, fixed, and subjected to ChIP with either EBF1 or HA antibodies. Relative enrichment of EBF1 versus 6ZFP in transduced *Ebf1*^*−/−*^ cells at "site a" is shown, with ChIP results for "site b" included as controls for EBF1 and 6ZFP occupancy. Data are expressed as fold enrichment over nontransduced *Ebf1*^*−/−*^ cells.\
(D) Single- or double-transduced cells from pMX and MigY-EBF1 transduced samples as well as pMX-ZF and MigY-EBF1 transduced samples were sorted for RNA 24 hr after infection and analyzed for relative expression of *Gata3* by qRT-PCR. Data are means ± SEMs of triplicate samples. Error bars indicate SEMs, ^\*^p \< 0.001. Data are representative of two separate experiments.\
See also [Figure S5](#app3){ref-type="sec"} and [Table S2](#app3){ref-type="sec"}.](gr5){#fig5}

![Decreased GATA3 Expression Is Essential for Early B Cell Development\
(A) Sorted e14.5 WT fetal liver LSKs were transduced with only pMX-6ZFP or MigY-EBF1 or both viruses, plated on OP9s, and analyzed for frequencies of viable B220^+^CD19^+^ cells on day 7. Double-transduced cells were identified as viable (DAPI^−^) GFP^+^YFP^+^ cells.\
(B) Sorted CD45^B6+^Flt3^+^ LSKs and CLPs from B6.CD45^SJL^ adults previously reconstituted with BM cells from C57BL/6 (CD45^B6^) backcrossed *Vav*^Cre^ or *Vav*^Cre^*Gata3*^fl/fl^ mice were transduced with pMX or pMX-6ZFP. Equal numbers of GFP^+^ cells were sorted into triplicate cytokine supplemented OP9 stromal cultures, and B cell differentiation was assessed 7 days later. Graphical data are means ± SEMs of triplicate samples.\
p \< 0.001.](gr6){#fig6}
